Symbols / XBIO
XBIO Chart
About
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.41M |
| Enterprise Value | 1.29M | Income | -3.16M | Sales | 2.86M |
| Book/sh | 2.56 | Cash/sh | 1.80 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | — | Forward P/E | -3.58 | PEG | — |
| P/S | 1.89 | P/B | 0.92 | P/C | — |
| EV/EBITDA | — | EV/Sales | 0.45 | Quick Ratio | 3.71 |
| Current Ratio | 4.56 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.04 | EPS next Y | -0.66 | EPS Growth | — |
| Revenue Growth | 67.20% | Earnings | 2025-11-12 16:00 | ROA | -31.56% |
| ROE | -57.43% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -53.04% | Profit Margin | -110.40% | Shs Outstand | 2.29M |
| Shs Float | 1.88M | Short Float | 0.73% | Short Ratio | 0.63 |
| Short Interest | — | 52W High | 13.93 | 52W Low | 1.90 |
| Beta | 2.31 | Avg Volume | 29.48K | Volume | 11.89K |
| Target Price | — | Recom | None | Prev Close | $2.21 |
| Price | $2.36 | Change | 6.70% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$2.36
Latest analyst target
3. DCF / Fair value
$-20.81
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.36
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-04-09 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-03-20 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-05 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-22 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-08-20 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2023-05-16 | down | HC Wainwright & Co. | Buy → Neutral | — |
- $4.5M offering: Xenetic Biosciences prices 735,000 shares to fund working capital - Stock Titan Fri, 10 Oct 2025 07
- Is Xenetic Biosciences Stock Built to Withstand More Downside? - Trefis Fri, 19 Dec 2025 08
- XBIO Shares Skyrocket: Exploring the Surge - StocksToTrade Wed, 08 Oct 2025 07
- Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates - Nasdaq ue, 12 Aug 2025 07
- Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock - ACCESS Newswire Fri, 10 Oct 2025 13
- Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real? - TechStock² Wed, 08 Oct 2025 07
- Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges - Benzinga Fri, 10 Oct 2025 07
- MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN - Innovators Driving Next Tech, Blockchain, AI Wave - More Stocks Inside - marketscreener.com hu, 09 Oct 2025 07
- XBIO Stock Alert: Riding the Market Waves - timothysykes.com Wed, 08 Oct 2025 07
- Xenetic Biosciences appoints James Parslow as interim CEO - Intellectia AI hu, 12 Feb 2026 11
- Xenetic Biosciences Inc. (XBIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Wed, 08 Oct 2025 14
- Groundbreaking Pancreatic Cancer Trial Launches: DNase I Combined With FOLFIRINOX in Advanced Cases - Stock Titan ue, 08 Jul 2025 07
- 15 Best High Volume Stocks to Buy Now - Yahoo Finance Fri, 30 Jul 2021 07
- XBIO Stock Price and Chart — NASDAQ:XBIO - TradingView Fri, 21 Jul 2017 02
- Aug Setups: Should you buy the dip on Georgia Power Company Preferred Security - July 2025 Closing Moves & Free Technical Confirmation Trade Alerts - baoquankhu1.vn Sat, 21 Feb 2026 15
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -4.20M | -4.52M | -6.69M | -5.71M |
| TotalUnusualItems | 0.00 | |||
| TotalUnusualItemsExcludingGoodwill | 0.00 | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -3.96M | -4.13M | -6.55M | -5.65M |
| ReconciledDepreciation | 0.00 | 27.04K | 35.48K | |
| EBITDA | -4.20M | -4.52M | -6.69M | -5.71M |
| EBIT | -4.20M | -4.52M | -6.72M | -5.75M |
| NetInterestIncome | 249.86K | 355.76K | 167.15K | 100.47K |
| InterestIncome | 249.86K | 355.76K | 167.15K | 100.47K |
| NormalizedIncome | -3.96M | -4.13M | -6.55M | -5.65M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -3.96M | -4.13M | -6.55M | -5.65M |
| TotalExpenses | 6.70M | 7.06M | 8.42M | 6.91M |
| TotalOperatingIncomeAsReported | -4.20M | -4.52M | -6.72M | -5.75M |
| DilutedAverageShares | 1.54M | 1.53M | 1.42M | 1.03M |
| BasicAverageShares | 1.54M | 1.53M | 1.42M | 1.03M |
| DilutedEPS | -2.57 | -2.71 | -4.61 | -5.50 |
| BasicEPS | -2.57 | -2.71 | -4.61 | -5.50 |
| DilutedNIAvailtoComStockholders | -3.96M | -4.13M | -6.55M | -5.65M |
| NetIncomeCommonStockholders | -3.96M | -4.13M | -6.55M | -5.65M |
| NetIncome | -3.96M | -4.13M | -6.55M | -5.65M |
| NetIncomeIncludingNoncontrollingInterests | -3.96M | -4.13M | -6.55M | -5.65M |
| NetIncomeContinuousOperations | -3.96M | -4.13M | -6.55M | -5.65M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -3.96M | -4.13M | -6.55M | -5.65M |
| OtherIncomeExpense | -5.71K | 25.38K | -1.60K | 1.12K |
| OtherNonOperatingIncomeExpenses | -5.71K | 25.38K | -1.60K | 1.12K |
| SpecialIncomeCharges | 0.00 | |||
| ImpairmentOfCapitalAssets | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 249.86K | 355.76K | 167.15K | 100.47K |
| InterestIncomeNonOperating | 249.86K | 355.76K | 167.15K | 100.47K |
| OperatingIncome | -4.20M | -4.52M | -6.72M | -5.75M |
| OperatingExpense | 6.70M | 7.06M | 8.42M | 6.91M |
| ResearchAndDevelopment | 3.29M | 3.49M | 4.77M | 3.16M |
| SellingGeneralAndAdministration | 3.42M | 3.56M | 3.65M | 3.74M |
| GeneralAndAdministrativeExpense | 3.42M | 3.56M | 3.65M | 3.74M |
| OtherGandA | 3.42M | 3.56M | 3.65M | 3.74M |
| TotalRevenue | 2.50M | 2.54M | 1.71M | 1.16M |
| OperatingRevenue | 2.50M | 2.54M | 1.71M | 1.16M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 2.70K | 2.70K | 2.70K | 2.70K |
| OrdinarySharesNumber | 1.54M | 1.54M | 1.52M | 1.34M |
| ShareIssued | 1.54M | 1.54M | 1.52M | 1.35M |
| TangibleBookValue | 6.01M | 9.79M | 13.64M | 18.39M |
| InvestedCapital | 6.01M | 9.79M | 13.64M | 18.39M |
| WorkingCapital | 5.69M | 8.78M | 12.58M | 17.30M |
| NetTangibleAssets | 6.01M | 9.80M | 13.65M | 18.39M |
| CommonStockEquity | 6.01M | 9.79M | 13.64M | 18.39M |
| PreferredStockEquity | 1.80K | 1.80K | 2.77K | 2.77K |
| TotalCapitalization | 6.01M | 9.80M | 13.65M | 18.39M |
| TotalEquityGrossMinorityInterest | 6.01M | 9.80M | 13.65M | 18.39M |
| StockholdersEquity | 6.01M | 9.80M | 13.65M | 18.39M |
| GainsLossesNotAffectingRetainedEarnings | 253.73K | 253.73K | 253.73K | 253.73K |
| OtherEquityAdjustments | 253.73K | 253.73K | 253.73K | 253.73K |
| TreasuryStock | 5.28M | 5.28M | 5.28M | 5.28M |
| RetainedEarnings | -197.19M | -193.23M | -189.10M | -182.55M |
| AdditionalPaidInCapital | 208.23M | 208.05M | 207.77M | 205.95M |
| CapitalStock | 3.35K | 3.35K | 4.29K | 16.24K |
| CommonStock | 1.54K | 1.54K | 1.52K | 13.46K |
| PreferredStock | 1.80K | 1.80K | 2.77K | 2.77K |
| TotalLiabilitiesNetMinorityInterest | 894.26K | 809.59K | 1.07M | 1.42M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 894.26K | 809.59K | 1.07M | 1.42M |
| OtherCurrentLiabilities | 34.20K | 48.26K | 39.95K | 66.20K |
| PayablesAndAccruedExpenses | 860.06K | 761.33K | 1.03M | 1.35M |
| CurrentAccruedExpenses | 576.45K | 520.50K | 745.85K | 992.43K |
| Payables | 283.62K | 240.83K | 287.36K | 362.47K |
| AccountsPayable | 283.62K | 240.83K | 287.36K | 362.47K |
| TotalAssets | 6.90M | 10.61M | 14.72M | 19.82M |
| TotalNonCurrentAssets | 313.92K | 1.02M | 1.07M | 1.09M |
| OtherNonCurrentAssets | 313.92K | 1.02M | 1.07M | 1.09M |
| NetPPE | 0.00 | |||
| AccumulatedDepreciation | -50.24K | |||
| GrossPPE | 50.24K | |||
| MachineryFurnitureEquipment | 50.24K | |||
| CurrentAssets | 6.59M | 9.59M | 13.65M | 18.72M |
| OtherCurrentAssets | 421.95K | 603.83K | 556.09K | |
| PrepaidAssets | 556.09K | 479.40K | ||
| CashCashEquivalentsAndShortTermInvestments | 6.17M | 8.98M | 13.10M | 18.24M |
| CashAndCashEquivalents | 6.17M | 8.98M | 13.10M | 18.24M |
| CashFinancial | 6.17M | 8.98M | 13.10M | 18.24M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -2.82M | -4.11M | -5.15M | -4.74M |
| IssuanceOfCapitalStock | 0.00 | 11.45M | ||
| CapitalExpenditure | -500.00K | |||
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 6.17M | 8.98M | 13.10M | 18.24M |
| BeginningCashPosition | 8.98M | 13.10M | 18.24M | 11.53M |
| ChangesInCash | -2.82M | -4.11M | -5.15M | 6.72M |
| FinancingCashFlow | 0.00 | 11.45M | ||
| CashFlowFromContinuingFinancingActivities | 0.00 | 11.45M | ||
| ProceedsFromStockOptionExercised | 0.00 | 3.68K | ||
| NetCommonStockIssuance | 0.00 | 11.45M | ||
| CommonStockIssuance | 0.00 | 11.45M | ||
| InvestingCashFlow | 0.00 | -500.00K | 0.00 | |
| CashFlowFromContinuingInvestingActivities | 0.00 | -500.00K | 0.00 | |
| NetIntangiblesPurchaseAndSale | 0.00 | -500.00K | 0.00 | |
| PurchaseOfIntangibles | 0.00 | -500.00K | 0.00 | |
| OperatingCashFlow | -2.82M | -4.11M | -4.65M | -4.74M |
| CashFlowFromContinuingOperatingActivities | -2.82M | -4.11M | -4.65M | -4.74M |
| ChangeInWorkingCapital | 970.98K | -262.73K | -426.69K | 461.19K |
| ChangeInOtherCurrentAssets | 704.43K | 48.58K | 25.00K | -281.95K |
| ChangeInPayablesAndAccruedExpense | 84.68K | -263.57K | -347.95K | 457.13K |
| ChangeInPayable | 84.68K | -263.57K | -347.95K | 457.13K |
| ChangeInAccountPayable | 84.68K | -263.57K | -347.95K | 457.13K |
| ChangeInPrepaidAssets | 181.87K | -47.73K | -103.74K | 286.01K |
| OtherNonCashItems | 1.79M | |||
| StockBasedCompensation | 171.81K | 283.08K | 511.48K | 410.44K |
| AssetImpairmentCharge | 0.00 | |||
| DeferredTax | 0.00 | |||
| DeferredIncomeTax | 0.00 | |||
| DepreciationAmortizationDepletion | 0.00 | 27.04K | 35.48K | |
| DepreciationAndAmortization | 0.00 | 27.04K | 35.48K | |
| Depreciation | 0.00 | 27.04K | 35.48K | |
| NetIncomeFromContinuingOperations | -3.96M | -4.13M | -6.55M | -5.65M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for XBIO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|